C urrent treatment for superficial transitional cell carcinoma ( TCC ) of the bladder is far from optimal. Although most superficial cancers can be managed with periodic transurethral resection, this is not an ideal situation because recurrence is the rule. 1 Moreover, up to 30% of such superficial tumors will evolve into more aggressive, potentially lethal cancers. Immunotherapy with intravesical bacillus Calmette -Guérin (BCG ) has effectively delayed progression in many cases, but unfortunately, this delay does not actually reflect a qualitative change in the underlying biology of the tumor, and patients continue to have substantial risk of eventually progressing to invasive, lifethreatening cancer. In fact, even with close surveillance and follow -up, at least 50% will eventually require a cystectomy, and 30% will die of metastatic bladder cancer within 15 years. 2, 3 Intravesical gene therapy, particularly using adenoviralmediated gene transfer, is a promising new approach for the treatment of refractory superficial bladder cancer. Intravesical delivery enables local administration and efficient delivery of therapeutic genes to cancer cells with minimal systemic exposure. In addition, the response to treatment can be easily monitored by cystoscopic examination, biopsy, and analysis of urine samples. Effective adenoviral -mediated gene therapy could also be possible for premalignant lesions, especially if the gene chosen could suppress the growth of genetically altered, but not yet malignant, cells and the treatment was relatively benign.
Progress in intravesical gene therapy, however, has been hampered by the lack of reproducible human tumor models available for superficial bladder cancer to develop novel therapeutic strategies. Fortunately, we have recently established a reproducible model for growing superficial human bladder cancer by intravesical instillation of human TCC cells into the bladders of athymic nude mice. 4 This model has allowed us to test strategies for overcoming the natural barrier to effective gene transfer across the urothelium.
Many mechanisms may interfere with adenoviral -mediated gene transfer and expression into the superficially growing TCC cells. The presence of secreted glycosaminoglycan ( GAG ) on the luminal surface of the bladder presents a physical barrier that inhibits the adherence of bacteria and viruses to the luminal epithelium. 5, 6 The relative lack of coxsackie -adenovirus receptor (CAR ) 7 on many tumor cells, 8 including those of bladder cancer origin, also has been a major concern in limiting adenoviral gene transfer. We now report that the simultaneous administration of adenovirus in a formulation containing the polyamide, Syn3, 9 markedly increases adenoviral -mediated gene transfer and expression not only in the normal urothelial cells but also in human superficial TCC growing within the bladder of athymic nude mice. In addition, this increased gene transfer was seen in tumor cells having little or no CAR. Therefore, using Syn3 to enhance intravesical adenoviral -mediated gene therapy should provide an opportunity for the first time to examine the efficacy of cancer gene therapy under conditions in which the majority of tumor and genetically altered urothelial cells 10 present can be transduced and express a therapeutic gene.
Materials and methods

Cell lines and adenoviral vectors
The human bladder cancer cell line, KU -7, was obtained and cultured as previously described. 4 The T24 cells were purchased from the American Type Culture Collection (Manassas, VA). rAd --gal was provided by the MD Anderson Cancer Center Viral Core Facility (Houston, TX ) or by Canji (San Diego, CA ). rAd --gal is an E1 -deleted, replication -deficient vector that encodes -galactosidase ( -gal ) under the control of the CMV promoter.
Intravesical instillation of human bladder cancer cells
The general method for producing superficial human bladder tumors in female athymic mice has been recently described. 4 Briefly, following anesthesia, a 24 -gauge angiocatheter was inserted into the bladder transurethrally and 100 L of 0.25% trypsin in 0.02% EDTA was infused. This was retained in the bladder for 30 minutes. After trypsinization, the bladder was recatheterized, washed with phosphate -buffered saline ( PBS ), and a 100-L suspension of PBS containing either 1Â10 7 KU -7 or T24 cells was instilled. The urethra was ligated with 6-0 silk suture and, after 3 hours, the suture was removed and the bladder was evacuated by spontaneous voiding.
b -Gal expression in vivo following simultaneous intravesical instillation of Syn3 or ethanol and rAd --gal Between 7 and 21 days after the KU -7 or T24 cells were injected intravesically, the mice were anesthesized and recatheterized. Subsequently, 50-100 L of a suspension containing rAd --gal [5Â10 9 infectious particles (IU )/ 7Â10 10 particles ( PN )/ 100 L ] was administered for 1 hour once, twice, or three times on consecutive days with or without Tween control vehicle. The dual exposure was given on two consecutive days, or on days 1 and 4, either alone or in the presence of Syn3 at a concentration of 0.2, 0.5, or 1 mg /mL in Tween vehicle. In some experiments, the enhanced gene transfer provided by Syn3 was compared to using 22% ethanol because ethanol had been shown previously to enhance intravesical adenoviral -mediated gene transfer. 11 The urethra was ligated similarly to the procedure used to inject bladder cancer cells described above to insure a consistent dose and 1-hour exposure. Forty -eight hours after the final administration, the mice were sacrificed. Bladders injected with T24 were treated similarly except that only a concentration of 1 mg /mL Syn3 was used. For analysis of -gal expression in vivo, the bladders were resected and frozen in liquid nitrogen. At times, the bladder was distended with OCT compound prior to being removed. Frozen sections were subsequently made, fixed in 1.25% glutaraldehyde for 5 minutes, incubated with X -gal (0.6 mg /mL ) overnight at 378C in a humidified atmosphere, and counterstained with eosin or nuclear fast red.
For the intravesical pig study, a female Yorkshire pig ( 30 kg) was anesthesized using isoflurane, and a Foley catheter was inserted through the urethra into the bladder. To determine the volume for filling the bladder, prior studies were conducted using a similar-sized pig that received varying amounts of contrast material prior to radiographic imaging. Optimal filling was obtained with 180 mL of instillate. The residual urine was removed from the bladder and washed with 180 mL of PBS prior to instillation of the adenoviral solution. The test material was prepared by dilution of the stock adenoviral solution ( rAd --gal ) 1:10 into a Tris -glycerol buffer ( 14 mM Tris, 10.9 mM sodium phosphate monobasic, 58.4 mM sucrose, 2 mM magnesium chloride, 1.086 M glycerol, pH 7.4 ) containing Syn3 (1 mg / mL ).The final concentration of rAd --gal was 1.1Â10 11 PN /mL. The solution was administered to the pig through the catheter for 1 hour. Following treatment, the solution was Figure 1 Adenoviral -mediated intravesical transfer to the urothelium with and without Syn3. No -gal -stained urothelial cells are seen after a single exposure to rAd --gal for 1 hour ( a ) and only a few cells show -gal staining after similar exposure for three consecutive days ( b ) ( magnification, Â10 ). c: -Gal staining in topmost layer of urothelial cells following one exposure to the same number of rAd --gal particles used in ( a ) in addition to 1 mg / mL Syn3. No -gal staining, however, is seen in many deeper layer urothelial cells ( magnification, Â10 ). d: -Gal staining throughout the urothelium as well as a few cells in the lamina propria after similar treatment as shown in ( c ), except that the bladder was exposed to the same number of viral particles for 1 hour on two consecutive days rather than receiving only one instillation ( magnification, Â20 ).
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High intravesical adenoviral-mediated gene transfer M Yamashita et al removed from the bladder, the bladder washed with 180 mL of PBS, and the animal was allowed to recover. After 24 hours, the treatment was repeated. The animal was sacrificed after 48 hours, and the bladder was fixed by intravesical instillation of whole organ fixative (2% neutral buffered formalin, 2% glutaraldehyde, 2 mM MgCl 2 , 10 mM PBS, pH 7.4 ) for 1 hour. Following fixation, the bladder was sectioned into strips, and washed for 24 hours at 48C in rinse buffer ( 2 mM MgCl 2 , 0.1% sodium deoxycholate, 0.2% IGEPAL -20, 10 mM PBS, pH 7.4 ). To detect transgene expression, the strips were submerged in chromogen (X -gal: 5-bromo -4 -chloro -3 -indolyl --D -galactopyranoside; Gibco, Rockville, MD ) for 4 hours. Following -gal staining, the strips were photographed and paraffinembedded for histological examination.
Results
Optimization of Syn3 intravesical therapy
Using our superficial bladder model, 4 we found minimal gene transfer in either the normal urothelium or human tumor cells growing superficially in the mouse bladder following one, two, or three intravesical instillations of rAd --gal for 1 hour (e.g., Fig 1, a and b) . In contrast, considerable gene transfer and expression occurred in the presence of Syn3. A significantly greater number of urothelial and tumor cells consistently showed -gal staining in bladders exposed once to 0.5 or 1 mg /mL Syn3 compared to 0.2 mg /mL Syn3. Moreover, we found that rAd --gal / Syn3 exposure on two consecutive days provided greater transgene expression than was observed when one intravesical treatment was given ( Fig 1, c and d ) . When only one instillation was done, some areas were left untransduced and the depth of urothelial Figure 2 Syn3 -enhanced adenoviral -mediated gene transfer. a: Diffuse -gal staining is seen in all the normal urothelium as well as the small KU -7 bladder tumor present ( indicated by an arrow ) in a bladder exposed to rAd --gal and 1 mg / mL Syn3 for 1 hour on two consecutive days ( magnification, Â4 ). b: Same section as seen in Figure 1a at Â10 magnification showing the staining of all KU -7 tumor cells ( again indicated with an arrow ). c: Hematoxylin and eosin ( H&E ) staining of a similar tumor region seen in Figure 1b at the same magnification ( Â10 ). d: The same KU -7 tumor section as shown in Figure 1c at Â40 magnification ( arrows indicate cells in mitosis ). e and f: Examples of an actual human CIS of the bladder and a papillary human bladder cancer are shown, respectively, at Â40. Note that the depth of tumor is similar ( in fact less ) than the depth of -gal tumor staining obtained by rAd --gal intravesical instillation in the presence of Syn3, suggesting that Syn3 may allow enhancement of gene transfer throughout the superficial tumor. g: -Gal staining of the human superficial tumor growing over the entire mouse bladder. The bladder was treated with 0.5 mg / mL rather than 1 mg / mL Syn3. All tumors cells present are seen to be stained similar to that in Figure 1 , a and b ( magnification, Â10 ). h: -Gal staining of CAR -negative T24 cells growing as superficial tumor ( magnification, Â4 ). Figure 3 Comparison between Syn3 and ethanol for enhancement of adenoviral -mediated gene transfer. a and b: -Gal staining of mouse bladder in which KU -7 bladder cancer cells are growing on the entire surface as a superficial tumor ( magnification, Â4 and Â10, respectively ). The mouse was treated intravesically with 1 mg / mL Syn3 and rAd --gal on two consecutive days similar to that shown for Figure 1, a and b ) . c and d: -Gal staining of a KU -7 tumor growing in mouse bladder after rAd --gal / ethanol treatment. -Gal staining is seen in KU -7 tumor cells after intravesical treatment with rAd --gal / 22% ethanol for 1 hour on two consecutive days using a similar protocol as previously published. 11 Significant staining is seen, but much less compared to Syn3 treatment under similar conditions ( magnification, Â4 and Â10, respectively ).
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High intravesical adenoviral-mediated gene transfer M Yamashita et al staining was less. In contrast, using the two -consecutiveday -instillation schedule, diffuse -gal staining was often seen in virtually all the normal urothelium as well as the bladder tumor present (Figs 1d and 2, a-d ) . The total cell depth of the tumor showing -gal staining was comparable to the depth of an actual human carcinoma in situ ( CIS ) lesion, or a more benign papillary bladder carcinoma ( Fig 2,  e and f, respectively ) . It should be noted that although treatment with 1 mg / mL Syn3 gave a more consistent -gal staining of the urothelium compared to using 0.5 mg / mL Syn3, nevertheless, a marked enhancement of rAd --gal gene transfer and -gal expression was often seen with 0.5 mg /mL Syn3 (Fig 2g) .
Because two exposures to Syn3 /rAd --gal for 1 hour on consecutive days resulted in very high adenoviral -mediated gene transfer and expression, we wished to examine if this schedule was optimal. We found that 1 hour of treatment on days 1 and 4 provided considerably less gene transfer than on consecutive days ( data not shown ). Using the days 1 and 4 schedule, complete transgene expression in all urothelial cells was never observed and the results were similar to that seen when treatment was only once.
Syn3 enhances gene transfer in tumor cells with absent CAR
Another obstacle to effective adenoviral -mediated gene therapy is the low level of CAR present in many human tumors, including bladder cancer. 8 The bladder cell line, T24, has little or no CAR and has been reported to be poorly infected by adenovirus in cell culture, allowing only 3-5% of the cells to be transfected at 10 multiplicity of infection ( MOI ). 8 We obtained a similar transfection frequency in our laboratory using these cells. However, when T24 tumors growing superficially in the bladder were treated intravesically with rAd --gal /Syn3 for 1 hour on two consecutive days, the majority of the tumor cells also showed -gal expression ( Fig 2h) . These results strongly suggest that Syn3 could be highly effective in increasing intravesical adenoviral -mediated gene transfer even in bladder tumors with low levels of CAR.
Comparison of advenoviral -mediated intravesical gene transfer with ethanol versus Syn3
It had previously been shown in a rat model that simultaneous intravesical administration of a 22% ethanol formulation together with rAd --gal can significantly increase adenoviral gene transfer and expression compared to rAd --gal -treated controls. 11 To compare the efficiency of ethanol-enhanced rAd --gal transfer and expression to that obtained with Syn3, KU -7 tumor-bearing mice received intravesical administration of rAd --gal in a 22% ethanol or 1 mg /mL Syn3 formulation for 1 hour once or on two consecutive days. Again, the best rAd --gal transfer and expression with ethanol were seen after two consecutive instillations ( Fig 3, c and d ) . However, the degree of transgene expression with ethanol was spotty throughout the bladder even under the most optimal treatment schedule and -gal staining was never as extensive as that seen with Syn3 ( e.g., compare Fig 3, a -c and b -d, respectively ) .
Increased adenoviral -mediated transgene expression by Syn3 in the pig urothelium
Although Syn3 increased adenovirus gene transfer to the urothelium of rats and mice, we felt it was desirable to determine whether Syn3 could also enhance gene transfer to the urothelium in larger nonrodent species as well. Because the pig bladder is similar to that of humans, we chose this species for testing gene transfer with Syn3. A female Yorkshire pig was administered rAd --gal intravesically for 1 hour in the presence of 1 mg /mL Syn3 on two consecutive days. As can be seen in Figure 4a , high levels of adenoviral transgene expression were obtained in the urothelium. Some portions of the urothelium were removed prior to -gal staining and were negative for -gal expression (Fig 4a ) , indicating that the staining was adenoviral -mediated and did not extend much deeper than the urothelium. To examine the depth of transgene expression more precisely, sections of the bladder were prepared and stained with hematoxylin and eosin. As seen in Figure 4b , high levels of -gal expression were observed throughout the urothelium. Modest expression was also often seen in cells within the upper portion of the lamina propria.
Discussion
It is our contention that cancer gene therapy as a modality for cancer treatment holds much promise, but has been hampered not because of a lack of highly effective genes for this purpose, but rather due to problems in gene delivery. Intravesical gene therapy would initially appear to be an excellent candidate for cancer gene therapy for many reasons. These include the need for better treatment of recurrent superficial bladder tumors, the ability to treat genetically altered urothelium that is in progression to CIS, the ease in gene delivery through a catheter, minimal 1Â10 11 PN / mL ) in a Syn3 formulation ( 1 mg / mL ) on two consecutive days. The animal was sacrificed 48 hours after the second treatment, the bladder was harvested, fixed, and cut into strips prior to determination of transgene expression by whole organ -gal staining. Depicted ( panel a ) is one representative strip of bladder showing the viral transgene expression that results from delivery of the adenovirus in a Syn3 formulation. Portions of the bladder epithelium were removed prior to rAd --gal staining to demonstrate that expression was specifically confined primarily to the urothelium. To determine the extent of -gal expression, pieces of the bladder were embedded in paraffin, and 5 -m sections stained with H&E ( b ). Transgene expression was primarily confined to the urothelium, with some minor expression observed in the lamina propria of the bladder -gal.
systemic exposure, and the ability to monitor various markers in urine or biopsy specimens. Nevertheless, because of the protective nature of the bladder wall, including the presence of the GAG layer, the degree of adenoviralmediated gene transfer and expression following intravesical installation in general has appeared to be low.
However, we have found that Syn3 has the potential to provide the means to greatly increase adenoviral -mediated gene transfer and expression through intravesical instillation. In the model system we utilized, treatment with Syn3 for 1 hour on two consecutive days produced consistently high gene transfer and expression. These results suggest that it may be possible to provide adenoviral -mediated gene transfer to the majority of the superficial tumor and genetically altered urothelial cells present in an actual clinical setting. Because this treatment schedule is not particularly difficult to accomplish, we expect to incorporate it into our planned intravesical trials for superficial bladder cancer.
In addition, significant gene transfer and expression were seen after two instillations of Syn3 in superficial tumors produced by a cell line, namely T24, which has little, if any, CAR. This suggests that Syn3 increases adenoviralmediated gene transfer by mechanisms in addition to interaction with the GAG layer. Therefore, Syn3 may provide a major contribution in overcoming many of the difficulties previously reported as potential problems allow sufficient gene transfer in superficial bladder tumors that have little or no CAR.
It should also be noted that following Syn3 exposure, we detected transgene expression in almost all the normal urothelial cells present in the mouse model as well as the full thickness of the urothelium in the pig. Although this might be considered a disadvantage because it is the primary goal to focus on cancer cells rather than normal urothelium, we believe instead that this degree of gene transfer could provide a great advantage for the treatment of recurrent superficial bladder cancer. A major problem with superficial bladder cancer is its frequent recurrence rate even with optimal local nongene therapy. This is caused, in part, by the fact that a ''field effect'' is usually present in these bladders whereby adjacent bladder tissue also contains numerous genetic alterations. 10 If we could adequately deliver genes intravesically and inhibit the growth of clinically occult disease including genetically altered, normal -appearing bladder cells, it could be highly effective in reducing tumor recurrence. The fact the Syn3 may facilitate gene transfer to the majority of morphologically normal -appearing but genetically altered bladder cells provides an opportunity to determine if specific genes can influence the growth of such cells.
